ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 250 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $56.82, for a total value of $14,205.00. Following the sale, the vice president now directly owns 56,738 shares in the company, valued at $3,223,853.16. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Meredith Cook also recently made the following trade(s):

• On Tuesday, August 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.62, for a total value of $14,905.00.
• On Friday, July 12th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $64.91, for a total value of $16,227.50.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP traded down $2.31 on Monday, hitting $56.20. The company had a trading volume of 353,537 shares, compared to its average volume of 204,411. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. The company’s fifty day moving average price is $61.39 and its 200-day moving average price is $63.93. The company has a market capitalization of $1.18 billion, a PE ratio of 35.04 and a beta of 0.71. ANI Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The business had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. During the same quarter in the previous year, the company earned $1.06 earnings per share. The company’s quarterly revenue was up 18.5% on a year-over-year basis. As a group, analysts predict that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Susquehanna Fundamental Investments LLC purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth approximately $228,000. The Manufacturers Life Insurance Company grew its holdings in shares of ANI Pharmaceuticals by 14.6% during the second quarter. The Manufacturers Life Insurance Company now owns 9,498 shares of the specialty pharmaceutical company’s stock worth $605,000 after buying an additional 1,211 shares in the last quarter. Millennium Management LLC raised its position in shares of ANI Pharmaceuticals by 1,005.8% in the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after buying an additional 209,272 shares during the last quarter. Maverick Capital Ltd. lifted its stake in shares of ANI Pharmaceuticals by 302.1% in the second quarter. Maverick Capital Ltd. now owns 18,536 shares of the specialty pharmaceutical company’s stock worth $1,180,000 after buying an additional 13,926 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C boosted its position in ANI Pharmaceuticals by 11.0% during the second quarter. Deerfield Management Company L.P. Series C now owns 5,138 shares of the specialty pharmaceutical company’s stock worth $327,000 after acquiring an additional 511 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

ANIP has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Wednesday, August 7th. Truist Financial reiterated a “hold” rating and issued a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. Finally, StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $77.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.